1) Freifeld AG, Bow EJ, Sepkowitz KA, et al : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis 52 : e56-93, 2011
2) Klastersky J : Febrile neutropenia. Curr Opin Oncol 5 : 625-632, 1993
3) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン. 南江堂, 東京, 2012
4) 日本癌治療学会 (編) : G-CSF適正使用ガイドライン2013年版. 金原出版, 東京, 2013
5) Bodey GP, Buckley M, Sathe YS, et al : Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 : 328-340, 1966
6) Kuderer NM, Dale DC, Crawford J, et al : Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106 : 2258-2266, 2006
7) Klastersky J, Paesmans M, Rubenstein EB, et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038-3051, 2000
8) Smith TJ, Khatcheressian J, Lyman GH, et al : 2006 up-date of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205, 2006
9) Aapro MS, Bohlius J, Cameron DA, et al : 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47 : 8-32, 2011
10) NCCN Clinical Practice Guidelines in Oncology-Myeloid growth factors : version 1, 2012
11) Haim N, Shulman K, Goldberg H, et al : The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol 22 : 229-232, 2005
12) NCCN Clinical Practice Guidelines in Oncology-Myeloid growth factors : version 2, 2016